



**Tatva Chintan Pharma Chem Limited**  
(Formerly known as Tatva Chintan Pharma Chem Private Limited)  
(CIN:L24232GJ1996PLC029894)



Date: 25 April 2022

Ref No: TCPCL/SEC/2022-23/00012

To,  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001  
**Scrip Code: 543321**

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla, Complex Bandra(E),  
Mumbai-400 051  
**Scrip Symbol: TATVA**

**Subject: Press Release on the financial results**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and year ended 31 March 2022.

The above information is also being made available on the website of the Company at [www.tatvachintan.com](http://www.tatvachintan.com).

This is for your information and records.

Thanking You,

Your Faithfully,  
**For Tatva Chintan Pharma Chem Limited**

**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**



Encl: As above

**Factory and Registered Office :** Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.  
**SEZ Unit :** Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.  
**DSIR Approved R & D Center :** Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.  
**Telephone No. :** +91 75748 48533 / 34 **Fax :** +91 265 263 8533  
**E-mail :** [chintan@tatvachintan.com](mailto:chintan@tatvachintan.com) **Website :** [www.tatvachintan.com](http://www.tatvachintan.com)

L 2288



## Tatva Chintan Pharma Chem Limited Q4FY22 & FY22 Financial Results

*FY22 Revenue grew 44% to ₹4,336 Mn on Y-o-Y basis*

*FY22 PAT grew 83% to ₹959 Mn on Y-o-Y basis*

Vadodara, 25<sup>th</sup> April 2022: Tatva Chintan Pharma Chem Limited (TCPCL) BSE: 543321, NSE: TATVA, ISIN: INEOGK401011, an integrated niche speciality chemical company, has announced its financial results for the quarter and year ended on 31 March 2022, as approved by the Board of Directors.

### Consolidated FY22 Results at Glance (Y-O-Y – FY22 COMPARED WITH FY21)

- **Revenue from Operations** for the year FY22 was ₹ 4,336 million higher by 44% vs FY21
- **EBITDA** was ₹ 1,171 million higher by 64%
- **EBIDTA Margin** for the year was at 27% vs 24% in FY21
- **Net Profit** was ₹ 959 million higher by 83%
- **Net Profit Margin** for the year was at 22% vs 17% in FY21
- **Basic and Diluted EPS** was ₹ 44.59 per share vs 26.02 in FY21

### Consolidated Results at Glance (Q-O-Q – Q4FY22 COMPARED WITH Q4FY21)

- **Revenue from Operations** for the quarter was ₹ 985 million, declined by 9%
- **EBITDA** for the quarter was ₹ 223 million, declined by 18%
- **EBIDTA Margin** for the quarter was at 23% vs 25% in Q4FY21
- **Net Profit** for the quarter was ₹ 175 million declined by 17%
- **Net Profit Margin** for the quarter was at 18% vs 19% in Q4FY21
- **Basic and Diluted EPS** for the quarter was ₹ 7.9 per share vs ₹ 10.5 in Q4FY21

### Update on the Product Categories

- **Phase Transfer Catalysts (PTCs)** comprised 23% of the revenue during FY22, reporting a revenue growth of nearly 20% y-o-y. These products are used as catalysts in manufacturing Pharmaceutical APIs, Flavors & Fragrances, Agrochemicals, etc.
- **Structure Directing Agents (SDAs)** comprised 52% of revenue during FY22, reported a very strong growth of 87% y-o-y in this segment. SDAs finds application in Automotive emission control, Petrochemicals, Continuous flow chemistry, etc.
- During FY22, **Electrolyte Salts (ES)** comprised 1.3% of our revenue and in absolute numbers revenue grew by more than 87% y-o-y. Electrolyte Salts are used in super capacitor batteries which find application in automobile, electronics and also for energy storage devices.
- Under the **Pharma Agro Intermediates and Specialty Chemicals (PASC) segment**, we have seen a y-o-y growth of 12% and revenue have crossed ₹ 1000 million contributing 24% to the revenue.

**Commenting on the year FY22 Mr. Chintan Shah, Managing Director**, said, for Tatva Chintan, FY22 has been a special year, as for the first time, we crossed the revenue mark of ₹ 4,000 million, we crossed an PBT of more than ₹ 1,000 million, our exports revenue crossed the mark of ₹ 3,000 million for the first time and in fact our export revenue of FY22 has exceeded the total revenue of FY21. Last and most memorable was successfully getting listed on Indian Stock Exchange.



We are pleased to inform you that on “together for sustainability” platform, we have drastically improved our Audit score from 54% to 87%. This is a matter of pride for TATVA CHINTAN and it also demonstrates our genuine efforts in moving towards sustainable solutions.

Our approach of being an integrated manufacturer, producing niche specialty chemical, having leadership position across product categories, diversified geographically with 79% exports as on FY22, focus on green chemistry by using cutting edge technology, in-house R&D facility with 24 employees including 10 senior highly qualified scientists has helped us steadily grow our presence and more importantly helped grow the customer’s confidence in TATVA CHINTAN, despite the turbulent macro-economic situation of covid lockdowns and geopolitical tensions globally.

We got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of ₹ 2,072.81 million, ₹ 129.59 million have been utilized during Q4FY22 taking the total amount utilized to ₹ 640.97 million as on 31 March 2022. The expansion is underway at our Dahej SEZ manufacturing plant and at our R&D facility at Vadodara.

#### **About Tatva Chintan Pharma Chem Limited (TCPCL):**

TCPCL is an Integrated Specialty Chemical company, present across the value chain manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts and Pharma & Agrochemical Intermediates and Specialty Chemicals, established in the year 1996 by first generation entrepreneur engineers. It has two manufacturing facilities at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor capacity of 280KL and 29 Assembly Lines, having Sophisticated R&D Unit recognized by DSIR at Vadodara, Gujarat. TCPCL has a customer base spanning over 25 Countries including USA, UK, China, Germany, Japan and South Africa. Exports constitute 79% of the total revenue during FY22. The Company is focused on serving customers across broad spectrum of chemical industries with applications in automotive, petrochemicals, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors & fragrances. For more information, please visit: [www.tatvachintan.com](http://www.tatvachintan.com)

**For Further details, please get in touch with:**



**Mr. Ashok Bothra**

CFO, Tatva Chintan Pharma Chem Limited

Email: [finance@tatvachintan.com](mailto:finance@tatvachintan.com)



**Ms. Krishna Patel, Mr. Rahul Thakur**

Investor Relations, EY

[krishna.patel2@in.ey.com](mailto:krishna.patel2@in.ey.com),

[rahul.thakur@in.ey.com](mailto:rahul.thakur@in.ey.com).

#### **Cautionary Statement:**

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward looking statements are subject to several known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward - looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Tatva Chintan Pharma Chem Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.